PMID- 38271561
OWN - NLM
STAT- MEDLINE
DCOM- 20240229
LR  - 20240229
IS  - 1557-8976 (Electronic)
IS  - 0882-8245 (Linking)
VI  - 37
IP  - 1
DP  - 2024 Jan-Feb
TI  - Interaction Between Genetic Susceptibility and COVID-19 Pathogenesis in Pediatric 
      Multisystem Inflammatory Disorders: The Role of Immune Responses.
PG  - 1-11
LID - 10.1089/vim.2023.0074 [doi]
AB  - Numerous studies have highlighted the emergence of coronavirus disease (COVID-19) 
      symptoms reminiscent of Kawasaki disease in children, including fever, heightened 
      multisystem inflammation, and multiorgan involvement, posing a life-threatening 
      complication. Consequently, extensive research endeavors in pediatric have aimed 
      to elucidate the intricate relationship between COVID-19 infection and the immune 
      system. COVID-19 profoundly impacts immune cells, culminating in a cytokine storm 
      that particularly inflicts damage on the pulmonary system. The gravity and 
      vulnerability to COVID-19 are closely intertwined with the vigor of the immune 
      response. In this context, the human leukocyte antigen (HLA) molecule assumes 
      pivotal significance in shaping immune responses. Genetic scrutiny of HLA has 
      unveiled the presence of at least one deleterious allele in children afflicted 
      with multisystem inflammatory syndrome in children (MIS-C). Furthermore, research 
      has demonstrated that COVID-19 exploits the angiotensin-converting enzyme 2 
      (ACE-2) receptor, transmembrane serine protease type 2, and various other genes 
      to gain entry into host cells, with individuals harboring ACE-2 polymorphisms 
      being at higher risk. Pediatric studies have employed diverse genetic 
      methodologies, such as genome-wide association studies (GWAS) and whole exome 
      sequencing, to scrutinize target genes. These investigations have pinpointed two 
      specific genomic loci linked to the severity and susceptibility of COVID-19, with 
      the HLA locus emerging as a notable risk factor. In this comprehensive review 
      article, we endeavor to assess the available evidence and consolidate data, 
      offering insights into current clinical practices and delineating avenues for 
      future research. Our objective is to advance early diagnosis, stabilization, and 
      appropriate management strategies to mitigate genetic susceptibility's impact on 
      the incidence of COVID-19 in pediatric patients with multisystem inflammation.
FAU - Chen, Li-Na
AU  - Chen LN
AD  - Department of Pediatric, Affiliated Hospital of Shaoxing University, Shaoxing, 
      China.
FAU - Shou, Zhang-Xuan
AU  - Shou ZX
AD  - Department of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese 
      Medical University, Hangzhou, China.
FAU - Jin, Xue
AU  - Jin X
AUID- ORCID: 0000-0002-9388-0558
AD  - Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang 
      Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical 
      College), Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240125
PL  - United States
TA  - Viral Immunol
JT  - Viral immunology
JID - 8801552
RN  - 0 (HLA Antigens)
RN  - pediatric multisystem inflammatory disease, COVID-19 related
SB  - IM
MH  - Humans
MH  - Child
MH  - *COVID-19/genetics/epidemiology/*complications
MH  - SARS-CoV-2
MH  - Genome-Wide Association Study
MH  - Inflammation
MH  - HLA Antigens/genetics
MH  - Immunity
MH  - Genetic Predisposition to Disease
MH  - *Systemic Inflammatory Response Syndrome
OTO - NOTNLM
OT  - COVID-19
OT  - genetic susceptibility
OT  - immune responses
OT  - multisystem inflammatory disorders
OT  - pediatric
EDAT- 2024/01/25 18:42
MHDA- 2024/02/29 06:43
CRDT- 2024/01/25 14:23
PHST- 2024/02/29 06:43 [medline]
PHST- 2024/01/25 18:42 [pubmed]
PHST- 2024/01/25 14:23 [entrez]
AID - 10.1089/vim.2023.0074 [doi]
PST - ppublish
SO  - Viral Immunol. 2024 Jan-Feb;37(1):1-11. doi: 10.1089/vim.2023.0074. Epub 2024 Jan 
      25.